exRNAdisease

Entry Detail

---



General Information

Database ID: exR0356682 RNA Name: hsa-miR-31-5p RNA Type: miRNA Chromosome: chr9 Starnd: - Coordinate: Start Site(bp): 21512158 End Site(bp): 21512178 External Links: hsa-miR-31-5p

Disease Information

Disease Name: Breast Cancer Disease Category: Cancers MeSH ID: D001943 Type: Neoplasms/Breast Neoplasms Alias: Breast Neoplasms//Breast Neoplasm//Neoplasm, Breast//Breast Tumors//Breast Tumor//Tumor, Breast//Tumors, Breast//Neoplasms, Breast//Breast Cancer//Cancer, Breast//Mammary Cancer//Cancer, Mammary//Cancers, Mammary//Mammary Cancers//Malignant Neoplasm of Breast//Breast Malignant Neoplasm//Breast Malignant Neoplasms//Malignant Tumor of Breast//Breast Malignant Tumor//Breast Malignant Tumors//Cancer of Breast//Cancer of the Breast//Mammary Carcinoma, Human//Carcinoma, Human Mammary//Carcinomas, Human Mammary//Human Mammary Carcinomas//Mammary Carcinomas, Human//Human Mammary Carcinoma//Mammary Neoplasms, Human//Human Mammary Neoplasm//Human Mammary Neoplasms//Neoplasm, Human Mammary//Neoplasms, Human Mammary//Mammary Neoplasm, Human//Breast Carcinoma//Breast Carcinomas//Carcinoma, Breast//Carcinomas, Breast

Expression Detail

GEO ID: GSE98181 Description: Circulating miRNA profiles from serum of women at high-risk for breast cancer Experimental Design: Cancer vs Control Case Disease Type: Breast Cancer Case Disease SubType: NA Case Sample: Breast Cancer Control Sample: Healthy Number of Case: 24 Number of Control: 24 Number of Samples: 48

Regulatory Relationship

mRNA targets: Gene Symbol Chromosome Start Site(bp) End Site(bp) Strand ABHD4 chr14 22598237 22613215 + ANKRD52 chr12 56237807 56258384 - BACH2 chr6 89926528 90296908 - CHD1 chr5 98853985 98928957 - CTNND1 chr11 57753243 57819546 + FAM222B chr17 28755978 28855232 - FURIN chr15 90868588 90883458 + GRK2 chr11 67266473 67286556 + HACD3 chr15 65530418 65578349 + HOXA7 chr7 27153716 27157936 - KIF3B chr20 32277651 32335011 + LONRF1 chr8 12721906 12756073 - MAP3K14 chr17 45263119 45317029 - PATL1 chr11 59636716 59669037 - PLCB1 chr20 8077251 8968360 + PPP1R3C chr10 91628442 91633071 - PRRC2B chr9 131373636 131500197 + RTL8B chrX 135020513 135022542 - RTL8C chrX 135032355 135033546 + SERF2 chr15 43777087 43802589 + SMAD3 chr15 67063763 67195169 + TRIM35 chr8 27284886 27311272 - XPNPEP3 chr22 40857077 40932815 + miRNA targets: NA circRNA targets: circRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand hsa_circ_0001728 chr7 99695763 99695845 - hsa_circ_0001349 chr3 152132729 152150709 + hsa_circ_0000241 chr10 70847874 70856944 + hsa_circ_0000931 chr19 38226804 38231095 - lncRNA targets: lncRNA Symbol Chromosome Start Site(bp) End Site(bp) Strand AC004832.5 chr22 30420512 30420912 + AC016876.2 chr17 7581964 7584086 - AC074117.1 chr2 27356246 27367622 + AC087477.2 chr15 96354237 96405235 + GAS5 chr1 173858559 173868882 - MAGI2-AS3 chr7 79452877 79471208 + MIR497HG chr17 7015818 7019659 - NEAT1 chr11 65422774 65445540 + SNHG16 chr17 76557764 76565348 + TUG1 chr22 30969245 30979395 + XIST chrX 73820649 73852723 - Display:

Experiment Detail

GEO ID: GSE98181 Sample Source: Blood Source Fraction: Serum Platform: GPL21572 Method: Microarray Num of detected RNA Type: 1 Num of detected RNAs of this Type: 2546 Sample treatment protocol: Serum is obtained from coagulated whole blood samples by centrifugation at 3000 rpm for 10 minutes. RNA Extract protocol: RNA was isolated from a 200ul serum aliquot using the miRNeasy Serum Plasma kit with ce-miR-39 spike-in (QIAGEN), QIAcube (QIAGEN) automation, and eluted with 14uL of nuclease-free water. RNA library preparation protocol: Exactly 8ul of RNA was tagged with a Poly-A tail, using an ATP driven reaction from the Affymetrix® FlashTag™ Biotin HSR RNA Labeling Kit.

Reference

PMID: 29348816 Title: Development of a predictive miRNA signature for breast cancer risk among high-risk women. Author: Farina NH, Ramsey JE, Cuke ME, Ahern TP, Shirley DJ, Stein JL, Stein GS, Lian JB, Wood ME Journal: Oncotarget. 2017 Nov 28;8(68):112170-112183. Description: We evaluated the ability of C-miRNAs to identify women most likely to develop breast cancer by profiling miRNA from serum obtained long before diagnosis.